中药在肥胖人群中减重效果优于利拉鲁肽:真实世界比较队列研究
本研究基于台湾长庚研究数据库(2013-2018)回顾性分析BMI≥25 kg/m²的肥胖人群,比较中药与利拉鲁肽治疗180天内体重和BMI变化。结果显示中药组体重下降更多(-4.5±4.07 kg vs -2.15±4.05 kg),且高血压不良事件更少(0.1% vs 2.7%)。结论提示中药在真实世界中可带来有临床意义的减重且无严重不良事件。
要点
- 中药组180天体重下降-4.5 kg,优于利拉鲁肽组的-2.15 kg。
- 中药组53.21%达到≥5%减重,利拉鲁肽组为22.46%。
- 中药组高血压不良事件发生率0.1%,低于利拉鲁肽组的2.7%。
核心结论
- 在真实世界肥胖人群中,中药治疗180天带来的体重和BMI下降优于利拉鲁肽,且未出现严重不良事件。
研究设计与样本
- 回顾性队列研究,数据来自长庚研究数据库(2013-2018),纳入BMI≥25 kg/m²的肥胖受试者共1360例,其中中药组701例、西药(利拉鲁肽)组659例,采用重叠权重平衡基线差异。
主要发现
- 第180天,中药组体重变化-4.5±4.07 kg,西药组-2.15±4.05 kg(p<0.001);BMI变化中药组-1.77±1.73,西药组-0.9±2.14(p<0.001)。
- 中药组53.21%(n=373)受试者体重下降≥5%,西药组为22.46%(p<0.001);中药组18.97%(n=132)下降≥10%,西药组为4.55%(p<0.001)。
- 不良事件方面,西药组659例中发生18例高血压(2.7%),中药组701例中仅1例(0.1%)。
- 基线时中药组更年轻(42.75±12.12岁 vs 52.31±11.7岁,p<0.001)、女性比例更高(77.6% vs 53.0%,p<0.001)、体重更低(79.83±15.66 kg vs 84.68±17.14 kg,p<0.001)、BMI更低(30.58±5.20 vs 32.84±6.95,p<0.001)。
临床怎么用
- 对于BMI≥25 kg/m²的肥胖患者,可考虑将中药作为体重控制的选项之一,尤其适用于不能耐受利拉鲁肽相关不良反应(如高血压)者。
- 治疗180天时中药组平均减重约4.5 kg,可作为临床预期效果参考。
局限性
- 本研究为回顾性真实世界研究,存在基线差异(如年龄、性别、体重),虽采用重叠权重平衡,但仍可能存在未测量混杂。
- 研究仅观察180天内效果,长期疗效和安全性未知。
- 中药组具体方剂组成未在摘要中报告,无法推广至特定中药方案。
- 不良事件仅报告高血压,其他潜在不良反应未详细分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction: In Taiwan, many people receive Chinese herbal medicine (CHM) as an alternative choice to help control body weight. However, the clinical effectiveness of CHM on weight control has not been well studied, while potential risks and adverse effects are still unknown. The aim of our study is to find out a safe and efficient treatment model of CHM for weight control compared to liraglutide in a real-world setting. Methods: we retrospectively analyzed obese subjects [body mass index (BMI)≧25 kg/m2] from Chang Gung Research Database (2013-2018). We evaluated the effect on body weight and BMI changes in obese groups receiving CHM or western medicine (WM, represented liraglutide) within 180 days. The proportion of subjects who achieved 5 and 10% weight reduction was calculated as well. Furthermore, the potential adverse events were analyzed during the study period. Overlap weighting was used to balance the baseline differences between CHM and WM groups. Results: The full cohort comprised 1,360 participants: 701 in the CHM group and 659 in the WM group. At baseline, the CHM group was younger (42.75 ± 12.12 years old in CHM vs. 52.31 ± 11.7 years old in WM, p-value <0.001) and has more female subjects (77.6% in CHM vs. 53.0% in WM, p-value <0.001). On the other hand, CHM users had lower body weight (79.83 ± 15.66 kg vs. 84.68 ± 17.14 kg, p-value <0.001) and BMI (30.58 ± 5.20 vs. 32.84 ± 6.95, p-value <0.001). At day 180, CHM users lost more body weight (-4.5 ± 4.07 kg vs. -2.15 ± 4.05 kg, p-value <0.001) and higher reduction in BMI (-1.77 ± 1.73 vs. -0.9 ± 2.14, p-value <0.001). A total of 53.21% (n = 373) CHM users lost at least 5% of body weight (22.46% for WM users, p-value <0.001), and 18.97% (n = 132) lost at least 10% of body weight (4.55% for WM users, p-value <0.001). The benefit remained consistent with and without overlap weighting. For adverse events, 18 cases of hypertension occurred in 659 subjects in the WM group (2.7%) in comparison to 1 of 701 subjects in the CHM group (0.1%). Conclusion: CHM led to clinically meaningful weight loss without serious adverse events in a real-world setting. Further clinical trials are warranted to validate this result.
引用
- Liao YN, Chen HY, Yang CW, et al. Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study. Front Pharmacol. 2022. PMID: 36160410. doi:10.3389/fphar.2022.978814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。